Allarity Therapeutics settles with Novartis for $1M

Item 1.01 Entry into a Material Definitive Agreement.

On October 28, 2026, Allarity

Therapeutics, Inc. (the "Company") entered into a Settlement and Release Agreement (the "Settlement Agreement") with Novartis Pharma AG ("Novartis") relating to an aggregate current liability of $4,900,000, plus interest, due to Novartis (the "Liability"). The Liability arose under a license agreement between Novartis and Allarity Therapeutics Europe ApS, an affiliate of the Company, which license agreement was previously terminated effective January 26, 2024.

Pursuant to the Settlement

Agreement, Novartis agreed to accept a payment of $1,000,000 from the Company as full payment of the Liability. Upon receipt of such payment, Novartis and its related parties will release the Company and its related parties from claims in respect of the Liability, and the Company and its related parties will release Novartis and its related parties from claims, subject in each case to claims relating to or arising from the enforcement of the Settlement Agreement¹.

The foregoing description of the Settlement Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Settlement

Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 8.01 Other Matters.

On October 30, 2026, the²

Company issued a press release announcing its first revenue-generating contract under its newly established CLIA-certified laboratory services strategy.^{2 2}A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference².

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

Description

10.1*

Settlement and Release Agreement, dated as of October 28, 2026, by and between Allarity Therapeutics, Inc. and Novartis Pharma AG.

99.1

Press Release, dated October 30, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

* Certain personally identifiable information has been omitted from this exhibit pursuant to Item 601(a)(6) of Regulation S-K. Redacted information is indicated by the notation "[***]".

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Allarity Therapeutics, Inc.

Date: November 2, 2026

By:

/s/ Thomas H. Jensen

Thomas H. Jensen

Chief Executive Officer

2

PRESS RELEASE, DATED OCTOBER 30, 2026

Exhibit 99.1

Allarity Therapeutics Secures First

Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue

- Agreement complements revenue from standard gene expression and DRP services⁴

- Development and validation services will support a European biotechnology company's precision oncology predictive device for use in the United States³

- Strategy expands commercial use of existing laboratory capabilities

- Stenoparib remains the Company's top development priority

TARPON SPRINGS, Fla., October 30, 2026 - Allarity Therapeutics,

Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)-a differentiated, dual PARP and WNT pathway inhibitor- today announced its first revenue-generating contract under its newly established CLIA-certified laboratory services strategy.

CLIA certification is a U.S. regulatory requirement for laboratories performing testing on specimens from humans, such as blood, body fluids, and tissue. T